Peter Weiden

10PUBLICATIONS

15CO-AUTHORS

Molecular medicinePharmacogenomicsPharmaceutical delivery technologiesSocial psychologyPredictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (10)

Sort by Publication Date:

|May 22, 2026

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction.

|Mar 23, 2026

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms.

William P Horan, Cory Saucier, Peter J Weiden

|Sep 29, 2025

Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia.

Peter J Weiden, Lauren N Strand, Michael J Doane

|Mar 20, 2025

Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia.

Leslie Citrome, Christoph U Correll, Andrew J Cutler

|Dec 03, 2022

Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia.

Christoph U Correll, Angel S Angelov, Andrew C Miller

|Nov 05, 2020

Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey.

Michael J Doane, Martha Sajatovic, Peter J Weiden

Pageof 2

Frequent Collaborators

Leslie Citrome

James A McGrory

Stephen R Marder

Henry A Nasrallah

Mark S Todtenkopf

Jakob B Bjorner

Dawn I Velligan

Christoph U Correll

Gregory W Mattingly

David McDonnell

Frequent Collaborators

Leslie Citrome

James A McGrory

Stephen R Marder

Henry A Nasrallah